Comparison of methods for identifying the optimal treatment duration in randomized trials for antibiotics
We conclude that the success of the next era in TB therapeutics duration evaluation trials, and antibiotics duration-ranging more broadly, will meaningfully rely on the ability to simultaneously pair innovative model-based statistical methods with re-imagined study designs such as MAMS-ROCI.
Authors
- Patrick P. J. Phillips (ORCID: https://orcid.org/0000-0002-6336-7024)
- Suzanne M. Dufault (ORCID: https://orcid.org/0000-0002-6316-6548)
- Brian H Aldana
Institutions
- University of California, San Francisco (US)
- University of California San Francisco Medical Center (US)
- Biostatistical Consulting (United States) (US)
Publication Details
- Journal
- Trials
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1186/s13063-025-09050-y
- Primary Topic
- Statistical Methods in Clinical Trials
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- University of California, San Francisco
- National Institute of Allergy and Infectious Diseases